|Videos|September 14, 2016

Cathy Belt on How to Act on Inherited Cancer Symptoms

Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.

Surveillance is important to monitor for any early signs of cancer, including earlier and more frequent screening to identify any abnormalities before they become cancerous.

Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.

Subscribe Now!

Cathy Belt on How to Act on Inherited Cancer Symptoms

Newsletter

Related Content

Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer?

Transportation, Logistics of Importance to Community Care With CDK4/6 Inhibitors

Stem Cell Transplant Nurse and NP Give Bone Marrow Donation

Chemo-Induced Myelosuppression Presentation and Management in ES-SCLC

What Biomarker Testing Is Required Up Front in Ovarian Cancer?

Latest CME

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Optimizing Multidisciplinary Care in TGCT

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Diagnosis and Management of TGCT

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(Pharmacist Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arizona

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer